Recombinant vWF can safely halt bleeding in vWD

There were no clinical signs of thrombotic events and no clinically significant abnormal D-dimer values post-treatment.

“These efficacy and safety data . . . represent a major advance in our quest to develop an optimal treatment for people living with vWD,” said study investigator Bruce Ewenstein, MD, PhD, of Baxalta, Inc.

“As this product is specifically designed to be administered without FVIII, it will allow physicians to dose vWF and FVIII separately and precisely based on the needs of each individual patient. This treatment strategy has the potential to become the standard of care for patients with severe von Willebrand disease.”